ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,22
-1,51%
Dow Jones
42 732,13
0,80%
DAX
19 906,08
-0,49%
Brent Oil
76,495
0,00%
Bitcoin
97 894,45
-0,21%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Exelixis Inc (EXEL) Cours

Exelixis Inc

Exelixis Inc (EXEL)

NASDAQ
33,97
0,03
(0,09%)
Fermé 04 Janvier 10:00PM
Retardé de 15 minutes
33,97
-0,02
(-0,06%)
Après les heures de négociation: 10:46PM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
33,97
Prix Achat
33,70
Prix Vente
34,28
Volume échangé
1 307 404
33,79 Fourchette du Jour 34,12
19,20 Plage de 52 semaines 36,97
Cap du marché
9,701B
Clôture Veille
33,94
Ouverture
33,79
Dernière Transaction
89
@
33.6843
Dernière heure de transaction
Volume financier
US$ 44 394 106
VWAP
33,9559
Volume moyen (3 m)
2 273 725
Actions en circulation
285 579 020
Rendement du Dividende
-
Ratio Cours sur Bénéfices
46,72
Bénéfice par action (BPA)
0,73
Chiffre d'affairess
1,83B
Bénéfice net
207,77M

À propos de Exelixis Inc

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under... Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
www.exelixis.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Exelixis Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker EXEL. Le dernier cours de clôture d'Exelixis était de US$33,94. Au cours de la dernière année, les actions de Exelixis ont été négociées dans une fourchette de prix de US$ 19,20 à US$ 36,97.

Exelixis compte actuellement 285 579 020 actions en circulation. La capitalisation boursière d'Exelixis est de US$9,69 milliard. Exelixis a un ratio cours/bénéfice (ratio PE) de 46.72.

EXEL Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

24 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

03 Décembre 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

29 Novembre 2024
Edgar (US Regulatory)

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

-- Presentations to be webcast on www.exelixis.com -- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor...

27 Novembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

27 Novembre 2024
Edgar (US Regulatory)

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib...

26 Novembre 2024
Business Wire

Form 144 - Report of proposed sale of securities

22 Novembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

20 Novembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

20 Novembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

20 Novembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.070.20648967551633.934.2533.25145007133.67444749CS
4-2.18-6.0304287690236.1536.21533.11200841734.21034864CS
128.2131.871118012425.7636.9725.76227372533.16143914CS
2611.8153.294223826722.1636.9721.82196780129.46416697CS
5210.1242.431865828123.8536.9719.2206134725.71535969CS
15615.7486.34119583118.2336.9714.87233403421.1061271CS
26016.6696.244945118417.3136.9713.67237356421.10769812CS

EXEL - Frequently Asked Questions (FAQ)

What is the current Exelixis share price?
The current share price of Exelixis is US$ 33,97
How many Exelixis shares are in issue?
Exelixis has 285 579 020 shares in issue
What is the market cap of Exelixis?
The market capitalisation of Exelixis is USD 9,69B
What is the 1 year trading range for Exelixis share price?
Exelixis has traded in the range of US$ 19,20 to US$ 36,97 during the past year
What is the PE ratio of Exelixis?
The price to earnings ratio of Exelixis is 46,72
What is the cash to sales ratio of Exelixis?
The cash to sales ratio of Exelixis is 5,3
What is the reporting currency for Exelixis?
Exelixis reports financial results in USD
What is the latest annual turnover for Exelixis?
The latest annual turnover of Exelixis is USD 1,83B
What is the latest annual profit for Exelixis?
The latest annual profit of Exelixis is USD 207,77M
What is the registered address of Exelixis?
The registered address for Exelixis is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the Exelixis website address?
The website address for Exelixis is www.exelixis.com
Which industry sector does Exelixis operate in?
Exelixis operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
FCUVFocus Universal Inc
US$ 0,9499
(174,93%)
260,91M
NITON2OFF Inc
US$ 2,6306
(145,85%)
358,26M
CRNCCerence Inc
US$ 19,33
(143,76%)
161,8M
KITTNauticus Robotics Inc
US$ 3,8249
(140,56%)
104,79M
ACONAclarion Inc
US$ 0,2984
(110,14%)
305,58M
HWHHWH International Inc
US$ 0,4621
(-28,80%)
7,43M
SMSTDefiance Daily Target 2x Short MSTR ETF
US$ 5,69
(-26,30%)
24,77M
RAINRain Enhancement Technologies Holdco Inc
US$ 5,59
(-23,42%)
161,15k
PTLEPTL Ltd
US$ 9,35
(-23,30%)
1,04M
NXUNXU Inc
US$ 0,725868
(-22,78%)
7,59M
NITON2OFF Inc
US$ 2,6306
(145,85%)
358,26M
TGLTreasure Global Inc
US$ 0,382
(101,58%)
337,49M
ACONAclarion Inc
US$ 0,2984
(110,14%)
305,58M
FCUVFocus Universal Inc
US$ 0,9499
(174,93%)
260,91M
NVDANVIDIA Corporation
US$ 144,47
(4,45%)
230M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
EXEL
Exelixis
BIT
UB4QE2
Unicredit Bank
BIT
UC5290
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés